Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b QT/QTc study of apalutamide in castration-resistant prostate cancer
NL-OMON47113Phase 1Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Johnson & Johnson. Primary endpoint: Effect on ventricular repolarization. Started Feb 2016; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON47113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47113.